Orthogonal Tri‐Modular Coiled‐Coil Assembly for Programmable Multi‐Cargo Display on Escherichia coli Nissle 1917
Source abstract
Abstract
ABSTRACT Live biotherapeutic products (LBPs) represent emerging living medicines capable of site‐specific intervention; however, current strategies for surface functionalization rely predominantly on static genetic fusion or covalent modification, limiting multiplexing and dynamic reconfiguration. Here, we engineer TriSCs (Tri‐specific Scaffold Cells), a tri‐modular and orthogonally programmable living scaffold based on Escherichia coli Nissle 1917. Three distinct α‐helical motifs are displayed on the bacterial outer membrane, forming a reconfigurable biointerface that enables spontaneous, highly specific, and reversible payload assembly via coiled‐coil interactions. This mix‐and‐go strategy allows simultaneous and selective recruitment of multiple functional modules without structural interference. Spatial co‐display of a DR5 agonistic nanobody and an EGFR‐targeting nanobody produces enhanced anticancer activity compared to soluble combinations, underscoring the impact of surface‐organized signaling. In parallel, modular incorporation of a fluorescent reporter enables real‐time bioimaging. By integrating orthogonality, reversibility, and multiplex capability within a single living chassis, TriSCs establish a dynamic and programmable LBP platform for precision theranostics and next‐generation bioengineered therapeutics.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Micro and Nano Robotics · Bacterial biofilms and quorum sensing · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering Pukyong National University Busan Republic of Korea
Funding
National Research Foundation of Korea
References (69)
Show source-provided references
1. 10.1038/s41467‐020‐15508‐110.1038/s41467‐020‐15508‐1 ↗
2. 10.1186/s12967-022-03609-y10.1186/s12967-022-03609-y ↗
3. 10.1016/j.mtbio.2023.10054310.1016/j.mtbio.2023.100543 ↗
4. 10.3390/cancers1622381010.3390/cancers16223810 ↗
5. 10.1177/175342591039625110.1177/1753425910396251 ↗
6. 10.1128/JB.184.21.5912‐5925.200210.1128/JB.184.21.5912‐5925.2002 ↗
7. 10.3390/cancers1617297110.3390/cancers16172971 ↗
8. 10.1111/1751‐7915.1352310.1111/1751‐7915.13523 ↗
9. 10.4161/gmic.2173710.4161/gmic.21737 ↗
10. 10.1016/j.tips.2022.02.00210.1016/j.tips.2022.02.002 ↗
11. 10.3109/0891060090344426710.3109/08910600903444267 ↗
12. 10.1158/1078‐0432.CCR‐23‐011810.1158/1078‐0432.CCR‐23‐0118 ↗
13. 10.1038/s41467‐020‐16602‐010.1038/s41467‐020‐16602‐0 ↗
14. 10.1016/j.copbio.2024.10310510.1016/j.copbio.2024.103105 ↗
15. 10.1038/s41467‐021‐26524‐010.1038/s41467‐021‐26524‐0 ↗
16. 10.1038/s42255‐023‐00897‐610.1038/s42255‐023‐00897‐6 ↗
17. 10.1016/j.biomaterials.2024.12302910.1016/j.biomaterials.2024.123029 ↗
18. 10.1002/smll.20200170510.1002/smll.202001705 ↗
19. 10.1038/s41587‐024‐02418‐610.1038/s41587‐024‐02418‐6 ↗
20. 10.7150/thno.1613510.7150/thno.16135 ↗
21. Nonpathogenic Escherichia Coli Engineered To Surface Display Cytokines as a New Platform For Immunotherapy
22. 10.1016/j.actbio.2023.07.05110.1016/j.actbio.2023.07.051 ↗
23. 10.1002/bit.2309510.1002/bit.23095 ↗
24. 10.1186/s12934‐021‐01528‐z10.1186/s12934‐021‐01528‐z ↗
25. 10.1002/cbic.20200010210.1002/cbic.202000102 ↗
26. 10.1002/bit.1030110.1002/bit.10301 ↗
27. 10.4014/jmb.2001.0105310.4014/jmb.2001.01053 ↗
28. 10.1039/C8SC00484F10.1039/C8SC00484F ↗
29. 10.1039/D0SC01878C10.1039/D0SC01878C ↗
30. 10.1038/nrd341010.1038/nrd3410 ↗
31. 10.3390/molecules2920494910.3390/molecules29204949 ↗
32. 10.1073/pnas.111548510910.1073/pnas.1115485109 ↗
33. 10.1038/s41467‐020‐14336‐710.1038/s41467‐020‐14336‐7 ↗
34. 10.1016/j.mtbio.2023.10066910.1016/j.mtbio.2023.100669 ↗
35. 10.1039/b914342b10.1039/b914342b ↗
36. 10.1016/j.chembiol.2024.06.00110.1016/j.chembiol.2024.06.001 ↗
37. 10.1016/j.addr.2020.12.01210.1016/j.addr.2020.12.012 ↗
38. 10.1021/acsomega.8b0015610.1021/acsomega.8b00156 ↗
39. 10.1074/jbc.M112.43134610.1074/jbc.M112.431346 ↗
40. 10.1021/bi060092q10.1021/bi060092q ↗
41. 10.1016/j.sbi.2008.04.00810.1016/j.sbi.2008.04.008 ↗
42. 10.1038/s41589‐019‐0443‐y10.1038/s41589‐019‐0443‐y ↗
43. 10.1073/pnas.100850210710.1073/pnas.1008502107 ↗
44. 10.1128/AEM.02499‐0710.1128/AEM.02499‐07 ↗
45. 10.4014/jmb.1309.0906610.4014/jmb.1309.09066 ↗
46. 10.1186/s13568‐020‐01097‐110.1186/s13568‐020‐01097‐1 ↗
47. 10.1110/ps.3940110.1110/ps.39401 ↗
48. 10.1039/D2SC02772K10.1039/D2SC02772K ↗
49. 10.1021/bi026845010.1021/bi0268450 ↗
50. 10.1021/acs.biomac.6b0183010.1021/acs.biomac.6b01830 ↗
51. 10.1016/j.bpj.2016.10.01010.1016/j.bpj.2016.10.010 ↗
52. 10.1016/S0959‐440X(00)00232‐310.1016/S0959‐440X(00)00232‐3 ↗
53. 10.1073/pnas.101534110810.1073/pnas.1015341108 ↗
54. 10.1038/nchembio.115310.1038/nchembio.1153 ↗
55. 10.1128/MCB.00520-0610.1128/MCB.00520-06 ↗
56. 10.5306/wjco.v6.i5.13310.5306/wjco.v6.i5.133 ↗
57. 10.4143/crt.2017.48710.4143/crt.2017.487 ↗
58. 10.3816/CCC.2003.n.00610.3816/CCC.2003.n.006 ↗
59. 10.1158/1078‐0432.CCR‐07‐139210.1158/1078‐0432.CCR‐07‐1392 ↗
60. 10.1016/j.jconrel.2024.10.06210.1016/j.jconrel.2024.10.062 ↗
61. 10.1159/00037399810.1159/000373998 ↗
62. 10.1016/j.ijpharm.2022.12174610.1016/j.ijpharm.2022.121746 ↗
63. 10.3389/fcell.2021.73368810.3389/fcell.2021.733688 ↗
64. 10.1016/j.jconrel.2022.07.00410.1016/j.jconrel.2022.07.004 ↗
65. 10.1016/j.drudis.2019.10.00210.1016/j.drudis.2019.10.002 ↗
66. 10.1016/j.chroma.2025.46572210.1016/j.chroma.2025.465722 ↗
67. 10.3390/antib1002001310.3390/antib10020013 ↗
68. Agonist DR5 Binding Polypeptides
69. 10.1002/ijc.2614510.1002/ijc.26145 ↗